WBP1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal liver tissue and left kidney tissue lysates, Primary antibody: P02302(WBP1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02302(WBP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P02302(WBP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The WW domain-binding protein 1 (WBP1) is a ubiquitously expressed adaptor protein known for its role in mediating protein-protein interactions, particularly through its binding to WW domains found in various signaling and regulatory proteins. WBP1 was initially identified as a partner of the Yes kinase-associated protein (YAP) and later linked to the Nedd4 family of E3 ubiquitin ligases, which are involved in substrate recognition during ubiquitination. Structurally, WBP1 contains multiple PPxY motifs that enable its interaction with WW domains, facilitating processes such as protein trafficking, transcriptional regulation, and post-translational modifications like ubiquitination. Dysregulation of WBP1 has been implicated in cancer, neurodegenerative disorders, and cardiovascular diseases, where it may influence cell proliferation, apoptosis, or stress response pathways.

WBP1 antibodies are essential tools for studying the protein's expression, localization, and function in these contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to detect WBP1 in biological samples. Some antibodies specifically target post-translational modifications (e.g., phosphorylation) or distinct isoforms of WBP1. aiding in mechanistic studies. Research utilizing WBP1 antibodies has contributed to understanding its role in modulating pathways like the Hippo signaling cascade and its interplay with oncogenic or tumor-suppressive networks. Validated WBP1 antibodies are critical for exploring its potential as a therapeutic target or diagnostic biomarker in disease models.